Automated liquid handler vendor vs third party plastic company.

by Dr John Comley
Winter 16/17
Competing for the disposable pipette tip business.
Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument ven...

3D cellular imaging - advances and considerations for high-content screening

By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick
Fall 16
Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for adva...

CRISPR Cas9: transforming gene editing in drug discovery labs

By Dr John Comley
Fall 16
It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducin...

Full length isoform sequencing yields a more comprehensive view of gene activity

By Luke Hickey
Fall 16
RNA-seq has revolutionised how scientists can interrogate gene expression. But after years of performing RNA-seq studies with short-read sequencers, many have realised that there is more...

I, robot. I, the future

Richard Holland
Fall 16
The Pistoia Alliance, whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector, is keenly in...

With synthetic biology, drug discovery is going virtual.

by Christopher Voigt
Summer 2016
Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him ar...

Metabolomics - a playbook for functional genomics

By Dr D Ferrick
Summer 2016
If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, diseas...

The coming of age of mass spectrometry imaging.

By Dr Peter J.H. Webborn and Dr Richard J.A. Goodwin
Spring 2016
Mapping complex drug distribution/retention in tissues, aligned with efficacy and safety biomarker localisation is now possible using label-free mass spectrometry imaging technologies.

Microtissues for in vitro toxicity assessment: Cost effective and in vivo relevant toxicology tools

By Dr Stephanie Ravenscroft, Dr Caroline Bauch, Dr Laura Hinton and Dr Paul Walker
Spring 2016
Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to accurately predict clinical toxicity s...

Preclinical imaging: improving translational power in oncology.

By Dr Todd Sasser
Spring 2016
Imaging has long been indispensable in clinical practice, and researchers have for many years used the same toolbox of imaging modalities as a component of their preclinical and drug deve...

Seeing within: Magnetic Resonance Imaging in drug development.

By Dr Geoff J.M. Parker
Winter 2015/16
Magnetic Resonance Imaging (MRI) can be used to provide quantitative measurements in the form of imaging biomarkers. These measurements have a number of attractive characteristics: They a...

New developments in single cell separation and analysis technologies.

By Dr John Comley Drug Discovery
Fall 2015
Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relat...

Epigenetic Targets : on the verge of becoming a major new category for successful drug research.

Summer 2015
By Dr John Comley
Most vendors of epigenetic modification proteins and reagents have enhanced and broadened their offerings in recent years. Of particular note is the increasing range of proteins and bindi...

Precise genome editing: the key to a CRISPR drug discovery pipeline?

By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr
Spring 2015
From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances in our understanding of DNA have raised hopes that its direct manipulatio...

Restucturing Proteomics: the rise of next-generation affinity reagents.

By Dr Paul Ko Ferrigno & Dr Jane McLeod
Winter 2014
The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value...

Advancing the promise of therapeutic genomic editing.

By Dr Morgan L. Maeder and Dr David Bumcrot
Fall 14
The development of genome editing technology is revolutionising the study of gene function and has the potential to usher in a new class of therapeutics for a broad range of diseases.